findmyKOL

Peter Ruane, MD

Enriched profile

Medical Director and Founder, Ruane Clinical Research · Ruane Clinical Research

ORCIDNPI
Region🇺🇸 Los Angeles, CA · West · United StatesSpecialtyInfectious DiseaseFocusHIV
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2019Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Peter Ruane is Medical Director and Founder, Ruane Clinical Research at Ruane Clinical Research. OpenAlex indexes 139 publications with 13,845 citations (h-index 51); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Infectious Disease profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Peter Ruane, MD, is Medical Director and Founder, Ruane Clinical Research. The public record shows 139 publications with 13,845 citations (h-index 51), centered on HIV. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 36 companies.

  • Most recent indexed publication: 2019 · Journal of viral hepatitis
  • Top research focus: HIV
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 36 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
HIV2 trialsHIV Infections2 trialsViral Hepatitis (B/C)1 trialHepatitis C1 trialHepatitis C, Chronic1 trialHepatitis, Chronic1 trial

Research focus

OpenAlex concept fingerprint
HIV

Drugs & molecules

across trials, industry payments and publications
Dovatogeneric · Dolutegravir / lamivudineClinical trialsIndustry payments111PublicationsCabenuvaClinical trialsIndustry payments82PublicationsApretudegeneric · CabotegravirClinical trialsIndustry payments48Publications

Works with

trial sponsors and companies reporting payments
ViiV Healthcare CompanyClinical trialsIndustry payments270Gilead Sciences, Inc.Clinical trialsIndustry payments75Napo Pharmaceuticals IncClinical trialsIndustry payments34

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
139publications

Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.

13,845citations

Total citations across indexed works.

51h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials
36companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    46.4%
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor13.4%
    Descovy83%Triumeq17%
    Part D<11 patients
    Protease Inhibitor10%
    Prezcobix51%Symtuza31%Prezista17%
    Part D<11 patients
  • Cardiovascular

    19.4%
    Statin8.4%
    Rosuvastatin Calcium56%Atorvastatin Calcium44%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)6%
    Losartan Potassium57%Olmesartan Medoxomil43%
    Part D<11 patients
  • Nervous system

    9.1%
    Gabapentinoids6%
    Gabapentin100%
    Part D11 patients
    SSRI3.1%
    Trazodone Hcl100%
    Part D<11 patients
6 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/company/ruane-clinical-research

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com
  • Other

    croiwebcasts.org/p/2020croi/croi/39

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →croiwebcasts.org

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    University College Dublin

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →suite401.com
  • Internal Medicine Residency

    Mayo Clinic (Rochester, MN)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →suite401.com
  • Research and Clinical Fellowship in Infectious Diseases

    West Los Angeles Veterans Affairs Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →suite401.com
  • Board Certified

    Infectious Diseases

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →suite401.com

Editorial & leadership roles

journal and society appointments

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Speaker/presenter

    "Therapeutic Interventions for HIV Treatment and Eradication" session, CROI 2020 (Conference on Retroviruses and Opportunistic Infections) webcast

    2020
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →croiwebcasts.org

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.